{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T13:31:02Z","timestamp":1747747862607},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1992,4,1]],"date-time":"1992-04-01T00:00:00Z","timestamp":702086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drug Ther"],"published-print":{"date-parts":[[1992,4]]},"DOI":"10.1007\/bf00054557","type":"journal-article","created":{"date-parts":[[2004,11,11]],"date-time":"2004-11-11T17:17:18Z","timestamp":1100193438000},"page":"111-124","source":"Crossref","is-referenced-by-count":5,"title":["Advances in thrombolytic therapy"],"prefix":"10.1007","volume":"6","author":[{"given":"M.","family":"Verstraete","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(87)92755-3","volume":"1","author":"GH Hall","year":"1987","unstructured":"Hall GH. Bolus streptokinase after myocardial infarction. Lancet 1987;1:96?97.","journal-title":"Lancet"},{"key":"CR2","first-page":"32","volume":"17","author":"M K\ufffdhler","year":"1987","unstructured":"K\ufffdhler M, Hellstern P, Doenecke P, et al. High-dose systemic streptokinase and acylated streptokinase-plasminogen complex (BRL 26921) in acute myocardial infarction: Alterations of the fibrinolytic system and clearance of fibrinolytic activity. Haemostasis 1987;17:32?39.","journal-title":"Haemostasis"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0002-9149(88)90880-6","volume":"62","author":"CM Gottlich","year":"1988","unstructured":"Gottlich CM, Cooper B, Schumacher JR, et al. Do different doses of intravenous streptokinase alter the frequency of coronary reperfusion in acute myocardial infarction? Am J Cardiol 1988;62:843?846.","journal-title":"Am J Cardiol"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/clc.4960100403","volume":"10","author":"C Cernigliano","year":"1987","unstructured":"Cernigliano C, Sansa M, Campi A, et al. Clinical experience with urokinase in intracoronary thrombolysis. Clin Cardiol 1987;10:222?230.","journal-title":"Clin Cardiol"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/0002-9149(85)90710-6","volume":"55","author":"DG Mathey","year":"1985","unstructured":"Mathey DG, Schofer J, Sheehan FH, et al. Intravenous urokinase in acute myocardial infarction. Am J Cardiol 1985;55:878?882.","journal-title":"Am J Cardiol"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0735-1097(91)91952-B","volume":"17","author":"M O'Rourke","year":"1991","unstructured":"O'Rourke M, Gallagher D, Healey J, et al. Paramedic-initiated pre-hospital thrombolyzing using urokinase in acute coronary occlusion (TICO 2). (abstr) J Am Coll Cardiol 1991;17:246.","journal-title":"J Am Coll Cardiol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0735-1097(87)80188-2","volume":"10","author":"HS Mueller","year":"1987","unstructured":"Mueller HS, Rao AK, Forman SA. Thrombolysis in myocardial infarction (TIMI): Comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1987;10:479?490.","journal-title":"J Am Coll Cardiol"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.V66.2.399.399","volume":"66","author":"G Agnelli","year":"1985","unstructured":"Agnelli G, Buchanan MR, Fernandez F, et al. Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits. Blood 1985;66:399?401.","journal-title":"Blood"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0049-3848(88)90071-0","volume":"52","author":"SF Badylak","year":"1988","unstructured":"Badylak SF, Voytik S, Klabunde RE, et al. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis. Thromb Res 1988;52:295?312.","journal-title":"Thromb Res"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1161\/01.CIR.79.1.125","volume":"79","author":"JP Clozel","year":"1989","unstructured":"Clozel JP, Tschopp T, Luedin E, Holvoet P. Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model. Circulation 1989;79:125?133.","journal-title":"Circulation"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0735-1097(87)80194-8","volume":"10","author":"PR Eisenberg","year":"1987","unstructured":"Eisenberg PR, Sherman L, Jaffe AS. Paradoxic elevation of fibrinopeptide A. Evidence for continued thrombosis despite intensive fibrinolysis. J Am Coll Cardiol 1987;10: 527?529.","journal-title":"J Am Coll Cardiol"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/01.CIR.79.4.929","volume":"79","author":"RM Prewitt","year":"1989","unstructured":"Prewitt RM, Shiffman F, Greenberg YD, et al. Recombinant tissue-type plasminogen activator in canine embolic pulmonary hypertension. Effects of bolus versus short-term administration on dynamics of thrombolysis and on pulmonary vascular pressure-flow characteristics. Circulation 1989;79:929?938.","journal-title":"Circulation"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"161S","DOI":"10.1378\/chest.97.4_Supplement.161S","volume":"97","author":"G Agnelli","year":"1990","unstructured":"Agnelli G. Rationale for bolus t-PA therapy to improve efficacy and safety. Chest 1990;97 (Suppl):161S-167S.","journal-title":"Chest"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00019501-199001000-00012","volume":"1","author":"B Tranchesi","year":"1990","unstructured":"Tranchesi B, Verstraete M, Vanhove P, et al. Intravenous bolus administration of recombinant tissue plasminogen activator to patients with acute myocardial infarction. Cor Artery Dis 1990;1:83?88.","journal-title":"Cor Artery Dis"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0002-9149(91)90737-6","volume":"68","author":"B Tranchesi","year":"1991","unstructured":"Tranchesi B, Chamone DF, Cobbaert C, et al. Coronary recanalization after intravenous bolus of alteplase in acute myocardial infarction. Am J Cardiol 1991;68:161?165.","journal-title":"Am J Cardiol"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/hrt.66.2.134","volume":"66","author":"JD Gemmill","year":"1991","unstructured":"Gemmill JD, Hogg KJ, MacIntyre PD, et al. A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction. Br Heart J 1991;66:134?138.","journal-title":"Br Heart J"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0735-1097(88)80040-8","volume":"12","author":"KL Neuhaus","year":"1988","unstructured":"Neuhaus KL, Tebbe U, Gottwik M, et al. Intravenous recombinant tissue plasminogen activator rt-PA and urokinase in acute myocardial infarction: Results of the German Activator Urokinase Study (GAUS). J Am Coll Cardiol 1988;12:581?587.","journal-title":"J Am Coll Cardiol"},{"key":"CR18","first-page":"S538","volume":"82","author":"TC Wall","year":"1990","unstructured":"Wall TC, Topol EJ, George BS, et al. The TAMI-7 trial of accelerated plasminogen activator dose regimens for coronary thrombolysis. (abstr) Circulation 1990;82:S538.","journal-title":"Circulation"},{"key":"CR19","first-page":"506","volume":"235","author":"M Verstraete","year":"1985","unstructured":"Verstraete M, Bounameaux H, De Cock F, et al. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in man. J Pharmacol Exp Ther 1985;235:506?512.","journal-title":"J Pharmacol Exp Ther"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0735-1097(89)90095-8","volume":"14","author":"CL Grines","year":"1989","unstructured":"Grines CL, Nissen SE, Booth DC, et al. A new thrombolytic regimen for acute myocardial infarction using combination half dose tissue-type plasminogen activator with full dose streptokinase: A pilot study. J Am Coll Cardiol 1989;14:573?580.","journal-title":"J Am Coll Cardiol"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/01.CIR.84.2.540","volume":"84","author":"CL Grines","year":"1991","unstructured":"Grines CL, Nissen SE, Booth DC, et al. and the KAMIT Study Group. A prospective, randomized trial comparing combinbation half-dose tissue-type plasminogen activator and streptokinase with full dose tissue-type plasminogen activator. Circulation 1991;84:540?549.","journal-title":"Circulation"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1161\/01.CIR.74.4.838","volume":"74","author":"D Collen","year":"1986","unstructured":"Collen D, Stassen JM, Stump DC, Verstraete M. In vivo synergism of thrombolytic agents. Circulation 1986;74: 838?842.","journal-title":"Circulation"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0002-9149(87)90280-3","volume":"60","author":"D Collen","year":"1987","unstructured":"Collen D, Van de Werf F. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction. Am J Cardiol 1987;60:431?434.","journal-title":"Am J Cardiol"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0002-9149(89)90464-5","volume":"64","author":"B Tranchesi","year":"1989","unstructured":"Tranchesi B, Bellotti G, Chamone D, Verstraete M. Effect of combined administration of saruplase and single-chain alteplase on coronary recanalization in acute myocardial infarction. Am J Cardiol 1989;64:229?232.","journal-title":"Am J Cardiol"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/01.CIR.77.5.1100","volume":"77","author":"EJ Topol","year":"1988","unstructured":"Topol EJ, Califf RM, George BS, et al. and the TAMI Study Group. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. Circulation 1988;77:1100?1107.","journal-title":"Circulation"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1161\/01.CIR.83.5.1543","volume":"83","author":"RM Califf","year":"1991","unstructured":"Califf RM, Topol EJ, Stack RS, et al. An evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction: The TAMI 5 randomized trial. Circulation 1991;83:1543?1556.","journal-title":"Circulation"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00019501-199104000-00013","volume":"2","author":"The Urokinase and Alteplase in Myocardial Infarction Study Group","year":"1991","unstructured":"The Urokinase and Alteplase in Myocardial Infarction Study Group. Combination of urokinase and alteplase in the treatment of myocardial infarction. Cor Artery Dis 1991;2:225?235.","journal-title":"Cor Artery Dis"},{"key":"CR28","doi-asserted-by":"crossref","unstructured":"Karsch KR, Ertl G, Kinkel B, et al. Systemic thrombolysis in acute myocardial infarction with pro-urokinase and urokinase (STAMP): Results of a randomized multicenter study (abstr). J Am Coll Cardiol 1990;15:3A.","DOI":"10.1016\/0735-1097(90)91741-C"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1161\/01.CIR.83.4.1429","volume":"83","author":"CJ Weinheimer","year":"1991","unstructured":"Weinheimer CJ, James HL, Kalyan NK, et al. Induction of sustained patency after clot-selective coronary thrombolysis with hybrid-B, a genetically engineered plasminogen activator with a prolonged biological half-life. Circulation 1991;83:1429?1436.","journal-title":"Circulation"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0002-9149(88)90108-7","volume":"61","author":"C Bode","year":"1988","unstructured":"Bode C, Schoenermark S, Schuler G, et al. Efficacy of intravenous urokinase and a combination of pro-urokinase and urokinase in acute myocardial infarction. Am J Cardiol 1988;61:971?974.","journal-title":"Am J Cardiol"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/0002-9149(89)90072-6","volume":"63","author":"DCL Gulba","year":"1989","unstructured":"Gulba DCL, Fischer K, Barthles M, et al. Low dose urokinase preactivated natural pro-urokinase for thrombolysis in acute myocardial infarction. Am J Cardiol 1989;63: 1025?1031.","journal-title":"Am J Cardiol"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/0002-8703(91)90179-L","volume":"121","author":"P Ott","year":"1991","unstructured":"Ott P, Fenster P. Combining thrombolytic agents to treat acute myocardial infarction. Am Heart J 1991;121:1583?1584.","journal-title":"Am Heart J"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1055\/s-0038-1646377","volume":"66","author":"HR Lijnen","year":"1991","unstructured":"Lijnen HR, Collen D. Strategies for the improvement of thrombolytic agents. Thromb Haemost 1991;66:88?110.","journal-title":"Thromb Haemost"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.1016\/S0021-9258(19)39416-5","volume":"265","author":"HR Lijnen","year":"1990","unstructured":"Lijnen HR, Nelles L, Van Hoef B, et al. Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and\/or duplication of structure\/functional domains. J Biol Chem 1990; 265:5677?5683.","journal-title":"J Biol Chem"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00005344-199008000-00004","volume":"16","author":"Z Wu","year":"1990","unstructured":"Wu Z, Van de Werf F, Stassen T, et al. Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like, and first kringle domains (amino acids 6?173) in a canine model. J Cardiovasc Pharmacol 1990;16:197?203.","journal-title":"J Cardiovasc Pharmacol"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-0038-1647479","volume":"65","author":"D Collen","year":"1991","unstructured":"Collen D, Lijnen HR, Vanlinthout I, et al. Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and\/or duplication of structural\/functional domains, in a hamster pulmonary embolism model. Thromb Haemost 1991;65: 174?180.","journal-title":"Thromb Haemost"},{"key":"CR37","unstructured":"Kohnert U, Rudolph R, Prinz H, et al. Production of a recombinant human tissue plasminogen activator variant (BM 06.022) from Escherichia coli using a novel renaturation technology. Fibrinolysis 1990;4 (Suppl 3):A116."},{"key":"CR38","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0038-1648190","volume":"65","author":"U Martin","year":"1991","unstructured":"Martin U, Fischer S, Kohnert U, et al. Thrombolysis with an Escherichia coli produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. Thromb Haemost 1991;65:560?564.","journal-title":"Thromb Haemost"},{"key":"CR39","doi-asserted-by":"crossref","first-page":"17120","DOI":"10.1016\/S0021-9258(19)76007-4","volume":"261","author":"DC Stump","year":"1986","unstructured":"Stump DC, Lijnen HR, Collen D. Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator. J Biol Chem 1986;261:17120?17126.","journal-title":"J Biol Chem"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1016\/S0021-9258(18)60606-4","volume":"263","author":"HR Lijnen","year":"1988","unstructured":"Lijnen HR, Nelles L. Holmes W, Collen D. Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu 144 through Leu 411) of recombinant single-chain urokinase-type plasminogen activator. J Biol Chem 1988;263:5594?5598.","journal-title":"J Biol Chem"},{"key":"CR41","doi-asserted-by":"crossref","first-page":"11826","DOI":"10.1016\/S0021-9258(18)99031-9","volume":"266","author":"HR Lijnen","year":"1991","unstructured":"Lijnen HR, Van Hoef B, De Cock F, et al. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem 1991;266:11826?11832.","journal-title":"J Biol Chem"},{"key":"CR42","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1055\/s-0038-1646440","volume":"66","author":"HR Lijnen","year":"1991","unstructured":"Lijnen HR, Stassen JM, Vanlinthout I, et al. Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis. Thromb Haemost 1991;66:468?473.","journal-title":"Thromb Haemost"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"17947","DOI":"10.1016\/S0021-9258(19)84664-1","volume":"264","author":"SJ Gardell","year":"1989","unstructured":"Gardell SJ, Duong LeT, Diehl RE, et al. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. J Biol Chem 1989;264:17947?17952.","journal-title":"J Biol Chem"},{"key":"CR44","unstructured":"Baldus B, Donner P, Boidal W, Schleuning WD. A novel plasminogen activator from the saliva of the vampire bat Desmodus rotundus. 6th GTH-Kongres, Kiel 1990."},{"issue":"Suppl 3","key":"CR45","first-page":"97","volume":"4","author":"RJ Shebuski","year":"1990","unstructured":"Shebuski RJ, Fujita T, Ramijt DR, et al. Thrombolytic efficacy of I.V. bolus vampire bat salivary plasminogen activator tPA in a rabbit model of femoral arterial thrombosis: Comparison to tissue-type plasminogen activator (t-PA) (abstr 248). Fibrinolysis 1990;4 (Suppl 3):97.","journal-title":"Fibrinolysis"},{"key":"CR46","first-page":"884","volume":"65","author":"B Baldus","year":"1991","unstructured":"Baldus B, Gehrmann G, Bringmann P, Donner P. Kinetics of Glu-plasminogen activation do not explain the fibrinolytic potency of recombinant Desmodus rotundus salivary plasminogen activator ?1 (rDSPA?1) (abstr). Thromb Haemost 1991;65:884.","journal-title":"Thromb Haemost"},{"key":"CR47","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1126\/science.4023710","volume":"229","author":"C Bode","year":"1985","unstructured":"Bode C, Matsueda GR, Hui KY, Haber E. Antibody-derived urokinase: A specific fibrinolytic agent. Science 1985;229:765?767.","journal-title":"Science"},{"key":"CR48","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0022-2828(87)80578-3","volume":"19","author":"C Bode","year":"1987","unstructured":"Bode C, Runge MS, Newell JB, et al. Thrombolysis by a fibrin-specific antibody Fab'-urokinase conjugate. J Mol Cell Cardiol 1987;19:335?341.","journal-title":"J Mol Cell Cardiol"},{"key":"CR49","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1021\/bi00404a012","volume":"27","author":"MS Runge","year":"1988","unstructured":"Runge MS, Bode C, Matsueda GR, Haber E. Conjugates to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro. Biochemistry 1988;27:1153?1157.","journal-title":"Biochemistry"},{"key":"CR50","unstructured":"Bode C, Runge MS, Matsueda GR, et al. Can intrinsic tissue-type plasminogen activator be concentrated at the site of a thrombus? (abstr). J Am Coll Cardiol 1987;9:81A."},{"key":"CR51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1432-1033.1989.tb15095.x","volume":"185","author":"M Dewerchin","year":"1989","unstructured":"Dewerchin M, Lijnen HR, Van Hoef B, et al. Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin. Eur J Biochem 1989;185:141?149.","journal-title":"Eur J Biochem"},{"key":"CR52","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1055\/s-0038-1646048","volume":"58","author":"PJ Declerck","year":"1987","unstructured":"Declerck PJ, Mombaerts P, Holvoet P, et al. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis. Thromb Haemost 1987;58: 1024?1029.","journal-title":"Thromb Haemost"},{"key":"CR53","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0268-9499(89)90046-5","volume":"3","author":"D Collen","year":"1989","unstructured":"Collen D, Dewerchin M, Stassen JM, et al. Thrombolytic and pharmacokinetic properties of conjugates or urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked heparin. Fibrinolysis 1989; 3:197?202.","journal-title":"Fibrinolysis"},{"key":"CR54","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0268-9499(05)80036-0","volume":"4","author":"M Dewerchin","year":"1990","unstructured":"Dewerchin M, Lijnen HR, Van Hoef B, et al. Characterization of conjugates of thrombin-treated single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin. Fibrinolysis 1990;4:19?26.","journal-title":"Fibrinolysis"},{"key":"CR55","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1073\/pnas.84.21.7659","volume":"84","author":"MS Runge","year":"1987","unstructured":"Runge MS, Bode C, Matsueda GR, Haber E. Antibody-enhanced thrombolysis targeting of tissue plasminogen activator in vitro. Proc Natl Acad Sci USA 1987;84: 7659?7662.","journal-title":"Proc Natl Acad Sci USA"},{"key":"CR56","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1161\/01.CIR.82.5.1744","volume":"82","author":"D Collen","year":"1990","unstructured":"Collen D, Dewerchin M, Rapold HJ, et al. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model. Circulation 1990; 82:1744?1753.","journal-title":"Circulation"},{"key":"CR57","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1073\/pnas.84.19.6904","volume":"84","author":"JM Schnee","year":"1987","unstructured":"Schnee JM, Runge MS, Matsueda GR, et al. Construction and expression of a recombinant antibody-targeted plasminogen activator. Proc Natl Acad Sci USA 1987;84: 6904?6908.","journal-title":"Proc Natl Acad Sci USA"},{"key":"CR58","doi-asserted-by":"crossref","first-page":"10819","DOI":"10.1016\/S0021-9258(18)61037-3","volume":"262","author":"C Bode","year":"1987","unstructured":"Bode C, Runge MS, Newell JB, et al. Characterization of an antibody-urokinase conjugate. A plasminogen activator targeted to fibrin. J Biol Chem 1987;262;10819?10823.","journal-title":"J Biol Chem"},{"key":"CR59","unstructured":"Charpie JR, Runge MS, Matsueda GR, et al. Enhancement of fibrinolysis by single chain urokinase (scu-PA) with a bifunctional antibody having both fibrin and scu-PA specificities (abstr). Clin Res 1988;36:436A."},{"key":"CR60","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1126\/science.2492113","volume":"243","author":"E Haber","year":"1989","unstructured":"Haber E, Quertermous T, Matsueda GR, et al. Innovative approaches to plasminogen activator therapy. Science 1989;243:51?56.","journal-title":"Science"},{"key":"CR61","first-page":"483","volume":"52","author":"C Bode","year":"1989","unstructured":"Bode C, Meinhardt G, Runge MS, et al. Conjugation of urokinase to an antiplatelet antibody results in a more potent fibrinolytic agent (abstr 1514). Thromb Haemost 1989;52:483.","journal-title":"Thromb Haemost"},{"key":"CR62","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood.V78.4.1005.1005","volume":"78","author":"M Dewerchin","year":"1991","unstructured":"Dewerchin M, Lijnen HR, Stassen JM, et al. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo. Blood 1991;78: 1005?1018.","journal-title":"Blood"},{"key":"CR63","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/0002-9149(91)90082-V","volume":"67","author":"MH Prins","year":"1991","unstructured":"Prins MH, Hirsh J. Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1991;67:3A-11A.","journal-title":"Am J Cardiol"},{"key":"CR64","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/01.CIR.79.2.281","volume":"79","author":"EJ Topol","year":"1989","unstructured":"Topol EJ, George BS, Kereiakes DJ, et al. for the TAMI Study Group. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989;79:281?286.","journal-title":"Circulation"},{"key":"CR65","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1056\/NEJM199011223232101","volume":"323","author":"J Hsia","year":"1990","unstructured":"Hsia J, Hamilton WP, Keiman N, et al. A randomized trial of heparin versus aspirin adjunctive to tissue plasminogen activator-induced thrombolysis for acute myocardial infarction. N Engl J Med 1990;323:1433?1437.","journal-title":"N Engl J Med"},{"key":"CR66","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/0002-9149(90)90525-6","volume":"66","author":"SD Bleich","year":"1990","unstructured":"Bleich SD, Nichols T, Schumacher R, et al. The role of heparin following coronary thrombolysis with tissue plasminogen activator (t-PA). Am J Cardiol 1990;66:1412?1417.","journal-title":"Am J Cardiol"},{"key":"CR67","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/hrt.67.2.122","volume":"67","author":"DP Bono de","year":"1992","unstructured":"de Bono DP, Simoons ML, Tijssen J, et al. for the ESCG. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomised double blind European Cooperative Study Group Trial. Br Heart J 1992;67: 122?128.","journal-title":"Br Heart J"},{"key":"CR68","unstructured":"Tebbe U. Thrombolysis with recombinant pro-urokinase in acute myocardial infarction: Role of heparin. In Abstracts of Sixth International Workshop, The George Washington University Medical Center, Dallas, November 11, 1990, p. 24."},{"key":"CR69","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0735-1097(86)80144-9","volume":"7","author":"PR Eisenberg","year":"1986","unstructured":"Eisenberg PR, Sherman L, Rich M, et al. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Cardiol 1986;7:1255?1262.","journal-title":"J Am Coll Cardiol"},{"key":"CR70","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/01.CIR.79.5.980","volume":"79","author":"HJ Rapold","year":"1989","unstructured":"Rapold HJ, Kuemmerli H, Weiss M, et al. Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 1989;79:980?989.","journal-title":"Circulation"},{"key":"CR71","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V72.2.616.616","volume":"72","author":"J Owen","year":"1988","unstructured":"Owen J, Friedman KO, Grossmann BA, et al. Thrombolytic therapy with tissue-type plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988;72:616?620.","journal-title":"Blood"},{"key":"CR72","doi-asserted-by":"crossref","unstructured":"Rapold HJ, de Bono D, Arnold AER, et al. for the European Cooperative Study Group. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. Circulation 1992;85.","DOI":"10.1161\/01.CIR.85.3.928"},{"key":"CR73","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1161\/01.CIR.83.5.1534","volume":"83","author":"PL Thompson","year":"1991","unstructured":"Thompson PL, Aylward PE, Federman J, et al. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. Circulation 1991;83:1534?1542.","journal-title":"Circulation"},{"key":"CR74","doi-asserted-by":"crossref","unstructured":"Agnelli G, Pascucci C, Cogmi B, Nenci GG. Effects of hirudin and heparin on the binding of new fibrin to the thrombus in t-PA treated rabbits. Thromb Haemost 1991, in press.","DOI":"10.1055\/s-0038-1646465"},{"key":"CR75","first-page":"223","volume-title":"Recent advances in blood coagulation","author":"B Hoet","year":"1991","unstructured":"Hoet B, Close P, Vermylen J, Verstraete M. Hirudo medicinalis and hirudin. In: Poller L, ed. Recent advances in blood coagulation. Edinburgh: Churchill Livingstone, 1991:223?244."},{"key":"CR76","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1055\/s-0038-1648151","volume":"65","author":"E Gray","year":"1991","unstructured":"Gray E, Watton J, Cesmeli S, et al. Experimental studies on a recombinant hirudin, CGP 39393. Thromb Haemost 1991;65:355?359.","journal-title":"Thromb Haemost"},{"key":"CR77","doi-asserted-by":"crossref","unstructured":"Mirshahi M, Soria J, Soria C, et al. Hirudin, contrary to heparin, does not induce platelet adhesion to blood clots and extracellular matrix in vitro (abstr). J Am Coll Cardiol 1991;16:51A.","DOI":"10.1016\/0735-1097(91)91172-B"},{"key":"CR78","unstructured":"R\ufffdbsamen K, Hornberger W, Schweden J, Kurf\ufffdrst M. Pharmacological characteristics of long-acting polyethylene glycol-coupled recombinant hirudin (LU 56471). Geneva 1991."},{"issue":"Suppl III","key":"CR79","first-page":"659","volume":"83","author":"JL Krstenansky","year":"1990","unstructured":"Krstenansky JL, Owen TJ, Yates MT, Mao SJT. Hirudin and hirudin C-terminal domains: Structural comparisons and antithrombin properties (abstr). Circulation 1990;83 (Suppl III):659.","journal-title":"Circulation"},{"issue":"Suppl III","key":"CR80","first-page":"659","volume":"82","author":"JW Fenton II","year":"1990","unstructured":"Fenton JW II, Witting JI, Bourdon P, Maragamor WCL. Thrombin specific inhibition by a novel hirudin analog (abstr). Circulation 1990;82 (Suppl III):659.","journal-title":"Circulation"},{"issue":"Suppl III","key":"CR81","first-page":"603","volume":"82","author":"A Kelly","year":"1990","unstructured":"Kelly A, Marzec U, Hanson S, et al. Potent antithrombotic effects of a novel hybrid antithrombin peptide in vivo (abstr). Circulation 1990;82 (Suppl III):603.","journal-title":"Circulation"},{"key":"CR82","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1055\/s-0038-1648156","volume":"65","author":"RJ Broersma","year":"1991","unstructured":"Broersma RJ, Kutcher LW, Henninger EF, et al. Antithrombotic activity of a novel C-terminal hirudin analog in experimental animals. Thromb Haemost 1991;65:377?381.","journal-title":"Thromb Haemost"},{"key":"CR83","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0735-1097(91)91171-A","volume":"17","author":"AV Kaplan","year":"1991","unstructured":"Kaplan AV, Leung LLK, Leung WH, et al. The effects of thrombin inhibition and antiplatelet membrane glycoprotein IIb\/IIIa on platelet deposition in an ex vivo angioplasty model (abstr). J Am Coll Cardiol 1991;17:51.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl III","key":"CR84","first-page":"277","volume":"82","author":"T Yasuda","year":"1990","unstructured":"Yasuda T, Gold HK, Leinbach RC, et al. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb\/IIIa antibody (abstr). Circulation 1990;82 (Suppl III):277.","journal-title":"Circulation"},{"key":"CR85","first-page":"145","volume":"83","author":"IK Jang","year":"1991","unstructured":"Jang IK, Gold HK, Leinbach RC, et al. Persistence of arterial eversion graft patency up to 24 hours following a one hour infusion of Argatroban, a selective thrombin inhibitor (abstr). Circulation 1991;83:145.","journal-title":"Circulation"},{"key":"CR86","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1161\/01.CIR.80.6.1918","volume":"80","author":"DJ Fitzgerald","year":"1989","unstructured":"Fitzgerald DJ. Platelet inhibition with an antibody to glycoprotein IIb\/IIIa. Circulation 1989;80:1918?1919.","journal-title":"Circulation"},{"key":"CR87","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.79.4.920","volume":"79","author":"IK Jang","year":"1989","unstructured":"Jang IK, Gold HK, Ziskind AA, et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with t-PA: A possible explanation for resistance to coronary thrombolysis. Circulation 1989;79:920?928.","journal-title":"Circulation"},{"key":"CR88","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1161\/01.CIR.83.5.1510","volume":"83","author":"R Clarke","year":"1991","unstructured":"Clarke R, Mayo G, FitzGerald GA, FitzGerald DJ. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991;83:1510?1518.","journal-title":"Circulation"},{"key":"CR89","first-page":"774","volume":"65","author":"DW Banner","year":"1991","unstructured":"Banner DW, Haavary P. Structural studies of inhibitor binding to the thrombin actin site (abstr). Thromb Haemost 1991;65:774.","journal-title":"Thromb Haemost"},{"issue":"Suppl III","key":"CR90","first-page":"659","volume":"83","author":"H Kotze","year":"1990","unstructured":"Kotze H, Lumsden A, Harker L, Hanson S. In vivo antithrombotic effects of local versus systemic therapy with potent antithrombins (abstr). Circulation 1990;83 (Suppl III):659.","journal-title":"Circulation"},{"key":"CR91","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1073\/pnas.85.9.3184","volume":"85","author":"H Harker","year":"1988","unstructured":"Harker H. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-propyl-arginyl chloromethyl ketone. Proc Natl Acad Sci USA 1988;85:3184?3188.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl III","key":"CR92","first-page":"603","volume":"82","author":"A Lumsden","year":"1990","unstructured":"Lumsden A, Kelly A, Dodisdon T, et al. Interruption of implanted vascular graft thrombosis by brief local therapy with D-Phe-Pro-Arg chloromethylketone (D-FPR CH2Cl) (abstr). Circulation 1990;82 (Suppl III):603.","journal-title":"Circulation"},{"key":"CR93","first-page":"774","volume":"65","author":"C Tapparelli","year":"1991","unstructured":"Tapparelli C, Powling M, Gfeller P, Metternich R. Novel boron containing thrombin inhibitor SDZ 217?766: In vitro and in vivo evaluation (abstr). Thromb Haemost 1991; 65:774.","journal-title":"Thromb Haemost"},{"key":"CR94","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1161\/01.CIR.77.6.1213","volume":"77","author":"V Fuster","year":"1988","unstructured":"Fuster V, Badimon L, Cohen M, et al. Insights into the pathogenesis of acute ischemic syndrome. Circulation 1988;77:1213?1220.","journal-title":"Circulation"},{"key":"CR95","doi-asserted-by":"crossref","first-page":"12C","DOI":"10.1016\/0002-9149(90)90109-E","volume":"65","author":"JH Chesebro","year":"1990","unstructured":"Chesebro JH, Badimon L, Fuster V. New approaches to treatment of myocardial infarction. Am J Cardiol 1990; 65:12C-9C.","journal-title":"Am J Cardiol"},{"key":"CR96","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1161\/01.CIR.75.1.243","volume":"75","author":"JYT Lam","year":"1987","unstructured":"Lam JYT, Chesebro JH, Steele PM, et al. Is vasospasm related to platelet deposition? Relationship in a porcine preparation of arterial artery in vivo. Circulation 1987; 75:243?248.","journal-title":"Circulation"},{"key":"CR97","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1161\/01.CIR.78.3.712","volume":"78","author":"JYT Lam","year":"1988","unstructured":"Lam JYT, Chesebro JH, Fuster V. Platelets, vasoconstriction and nitroglycerin during arterial wall injury: A new antithrombotic role for an old drug. Circulation 1988;78: 712?716.","journal-title":"Circulation"},{"key":"CR98","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.76.1.142","volume":"76","author":"JH Chesebro","year":"1987","unstructured":"Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142?154.","journal-title":"Circulation"},{"key":"CR99","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/eurheartj\/8.suppl_F.55","volume":"8","author":"PW Serruys","year":"1987","unstructured":"Serruys PW, Arnold AER, Brower RW. Effects of continued rt-PA administration on the residual stenosis after initially successful recanalization in acute myocardial infarction: A quantitative coronary angiographic study of a randomized trial. Eur Heart J 1987;8:1172?1181.","journal-title":"Eur Heart J"},{"key":"CR100","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1161\/01.CIR.80.5.1166","volume":"80","author":"KP Rentrop","year":"1989","unstructured":"Rentrop KP, Feit F, Blanke H, et al. Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Circulation 1989;80: 1166?1175.","journal-title":"Circulation"},{"key":"CR101","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/0735-1097(90)90298-4","volume":"16","author":"J Lierde Van","year":"1990","unstructured":"Van Lierde J, De Geest H, Verstraete M, et al. Angiographic assessment of the infarct-related coronary stenosis after spontaneous or therapeutic thrombolysis. J Am Coll Cardiol 1990;16:1545?1549.","journal-title":"J Am Coll Cardiol"},{"key":"CR102","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1161\/01.CIR.78.6.1335","volume":"78","author":"S Nakagawa","year":"1988","unstructured":"Nakagawa S, Hanada Y, Koiwaya Y, et al. Angiographic features in the infarct-related artery after intracoronary urokinase followed by prolonged anticoagulation. Role of ruptured atheromatous plaque and adherent thrombus in acute myocardial infarction in vivo. Circulation 1988;78: 1335?1344.","journal-title":"Circulation"},{"issue":"Suppl III","key":"CR103","first-page":"200","volume":"82","author":"L Wallentin","year":"1990","unstructured":"Wallentin L, Nyman I, and the Risk Study Group. Low dose aspirin is an effective treatment of silent myocardial infarction (abstr). Circulation 1990;82 (Suppl III):200.","journal-title":"Circulation"},{"key":"CR104","first-page":"158","volume":"12","author":"P Gresele","year":"1991","unstructured":"Gresele P, Deckmyn H, Nenci GG, Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. TIPS 1991;12: 158?163.","journal-title":"TIPS"},{"key":"CR105","first-page":"169","volume":"81","author":"GI Fiddler","year":"1990","unstructured":"Fiddler GI, Lumley P. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review. Circulation 1990;81:169?178.","journal-title":"Circulation"},{"key":"CR106","first-page":"1178","volume":"65","author":"E Perzborn","year":"1991","unstructured":"Perzborn E, Seuter F. The action of BAY U 3405, a specific thromboxane (Tx) A2 antagonist, in models of thromboembolism and sudden death (abstr). Thromb Haemost 1991;65:1178.","journal-title":"Thromb Haemost"},{"key":"CR107","first-page":"484","volume":"248","author":"GI Grover","year":"1989","unstructured":"Grover GI, Schumacher WA. Effect of the thromboxane A2 receptor antagonist SQ 30,741 on ultimate myocardial infarct size: Reperfusion injury and coronary flow reserve. J Pharmacol Exp Ther 1989;248:484?491.","journal-title":"J Pharmacol Exp Ther"},{"key":"CR108","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/0002-8703(91)90708-P","volume":"121","author":"GJ Grover","year":"1991","unstructured":"Grover GJ, Parham CS, Schumacher WA. The combined antiischemic effects of the thromboxane receptor antagonist SQ 30,741 and tissue-type plasminogen activator. Am Heart J 1991;121:426?433.","journal-title":"Am Heart J"},{"key":"CR109","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1172\/JCI113223","volume":"80","author":"P Gresele","year":"1987","unstructured":"Gresele P, Arnout J, Deckmyn H, et al. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis, studies with thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Invest 1987;80: 1435?1445.","journal-title":"J Clin Invest"},{"key":"CR110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1055\/s-0038-1647258","volume":"64","author":"B Hoet","year":"1990","unstructured":"Hoet B, Arnout J, Van Geet C, et al. Ridogrel, a combined synthase inhibitor and receptor blocker, decreases elevated plasma ?-thromboglobulin levels in patients with documented peripheral arterial disease. Thromb Haemost 1990;64:87?90.","journal-title":"Thromb Haemost"},{"key":"CR111","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1172\/JCI114813","volume":"86","author":"P Golino","year":"1990","unstructured":"Golino P, Rosolowsky M, Yao SK, et al. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. J Clin Invest 1990;86:1095?1102.","journal-title":"J Clin Invest"},{"key":"CR112","first-page":"277","volume":"17","author":"F Werf Van de","year":"1991","unstructured":"Van de Werf F, Wu Z, Stassen TM, et al. Dual platelet thromboxane A2 synthase inhibition\/endoperoxide receptor blockade (Ridogrel) and\/or aspirin enhance thrombolysis with rt-PA in canine coronary arteries (abstr). J Am Coll Cardiol 1991;17 (Suppl):277.","journal-title":"J Am Coll Cardiol"},{"key":"CR113","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/0735-1097(91)91173-C","volume":"17","author":"A Water Van de","year":"1991","unstructured":"Van de Water A, Xhonneux R, De Clerck F. Willerson JT. Heparin enhances the synergism between platelet TXA2 synthase inhibitor\/receptor blockade (Ridogrel) and tissue plasminogen activator in lysing canine coronary thrombi (abstr). J Am Coll Cardiol 1991;17 (Suppl):52.","journal-title":"J Am Coll Cardiol"},{"key":"CR114","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/0735-1097(91)91424-D","volume":"17","author":"HJ Rapold","year":"1991","unstructured":"Rapold HJ, Van de Werf F, De Geest H, et al. Pilot study of combined administration of Ridogrel and t-PA in patients with acute myocardial infarction (AMI) (abstr). J Am Coll Cardiol 1991;17 (Suppl):114.","journal-title":"J Am Coll Cardiol"},{"key":"CR115","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/0092-8674(91)90261-V","volume":"64","author":"TH Vu","year":"1991","unstructured":"Vu TH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64:1057?1068.","journal-title":"Cell"},{"key":"CR116","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1055\/s-0038-1648180","volume":"65","author":"R Caterina De","year":"1991","unstructured":"De Caterina R, Sicari R, Bernini W, et al. Benefit\/risk profile of combined antiplatelet therapy with ticlopidine and aspirin. Thromb Haemost 1991;65:504?510.","journal-title":"Thromb Haemost"},{"key":"CR117","first-page":"1178","volume":"65","author":"T Lecompte","year":"1991","unstructured":"Lecompte T, Lecribier C, Bouloux C, et al. Potential value of the combination of ticlopidine and aspirin. Effect of the addition of 40 mg daily aspirin to ticlopidine treatment in healthy volunteers (abstr). Thromb Haemost 1991;65:1178.","journal-title":"Thromb Haemost"},{"key":"CR118","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1161\/01.CIR.80.6.1766","volume":"80","author":"BS Coller","year":"1989","unstructured":"Coller BS, Folts JD, Smith SR, et al. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GP IIb\/IIIa receptor. Correlation with bleeding time, platelet aggregation and blockade of GP IIb\/IIIa receptors. Circulation 1989;80:1766?1774.","journal-title":"Circulation"},{"key":"CR119","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1172\/JCI113286","volume":"81","author":"SR Hanson","year":"1988","unstructured":"Hanson SR, Paretti FI, Ruggeri ZM, et al. Effects of monoclonal antibodies against the platelet glycoprotein IIb\/IIIa complex on thrombosis and hemostasis in the baboon. J Clin Invest 1988;81:149?158.","journal-title":"J Clin Invest"},{"key":"CR120","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1172\/JCI113446","volume":"81","author":"I Yasuda","year":"1988","unstructured":"Yasuda I, Gold HK, Fallon JT, et al. Monoclonal antibody against the platelet glycoprotein (GP) IIb\/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988;81:1284?1291.","journal-title":"J Clin Invest"},{"key":"CR121","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/01.CIR.77.3.670","volume":"77","author":"HK Gold","year":"1988","unstructured":"Gold HK, Coller B, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb\/IIIa antibody in a canine preparation. Circulation 1988;77:670?677.","journal-title":"Circulation"},{"issue":"Suppl 3","key":"CR122","first-page":"413","volume":"5","author":"S Bhattacharva","year":"1991","unstructured":"Bhattacharva S, Mackie I, Machin S, et al. Inhibition of platelet function by GPIIb\/IIIa (7E3) FAB murine monoclonal antibody: Phase-1 clinical studies (abstr). Cardiovasc Drugs Ther 1991;5 (Suppl 3):413.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"Suppl III","key":"CR123","first-page":"370","volume":"82","author":"L Badimon","year":"1990","unstructured":"Badimon L, Badimon J, Ruggeri Z, Fuster V. A peptide-specific monoclonal antibody that inhibits von Willebrand factor binding to GPIIb\/IIIa inhibits platelet deposition to human atherosclerotic vessel wall (abstr). Circulation 1990;82 (Suppl III):370.","journal-title":"Circulation"},{"key":"CR124","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0092-8674(90)90230-C","volume":"62","author":"L Osborn","year":"1990","unstructured":"Osborn L. Leukocytes adhesion to endothelium in inflammation. Cell 1990;62:3?6.","journal-title":"Cell"},{"key":"CR125","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/0304-4165(83)90059-4","volume":"757","author":"C Ouyang","year":"1983","unstructured":"Ouyang C, Huang TF. Platelet aggregation inhibitor from Trimeresurus gramineus snake venom. Biochim Biophys Acta 1983;757:332?341.","journal-title":"Biochim Biophys Acta"},{"key":"CR126","doi-asserted-by":"crossref","first-page":"16157","DOI":"10.1016\/S0021-9258(18)47710-1","volume":"262","author":"TF Huang","year":"1987","unstructured":"Huang TF, Holt JC, Lukasiewicz H, Niewiarowski S. Trigamin, a low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed in glycoprotein IIb\/IIIa complex. J Biol Chem 1987;262:16157?16163.","journal-title":"J Biol Chem"},{"key":"CR127","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1021\/bi00428a037","volume":"28","author":"TF Huang","year":"1989","unstructured":"Huang TF, Holt JC, Kirby EP, Niewiarowski S. Trigamin: Primary structure and its inhibition on von Willebrand binding to glycoprotein IIb\/IIIa complex on human platelets. Biochemistry 1989;28:661?666.","journal-title":"Biochemistry"},{"key":"CR128","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1055\/s-0038-1665535","volume":"65","author":"CM Teng","year":"1991","unstructured":"Teng CM, Huang TF. Inventory of exogenous inhibitors of platelet aggregation. Thromb Haemost 1991;65:624?626.","journal-title":"Thromb Haemost"},{"issue":"Suppl III","key":"CR129","first-page":"370","volume":"82","author":"S Niewiarowski","year":"1990","unstructured":"Niewiarowski S, Cook JJ, Stewart GJ, Gould RJ. Structural requirements for expression of antiplatelet activity of disintegrins (abstr). Circulation 1990;82 (Suppl III):370.","journal-title":"Circulation"},{"key":"CR130","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1161\/01.CIR.83.3.1038","volume":"83","author":"T Yasuda","year":"1991","unstructured":"Yasuda T, Gold HK, Leinbach RC, et al. Kristin, a polypeptide platelet GPIIb\/IIIa receptor antagonist, enhances and sustains coronary artery thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation 1991;83:1038?1047.","journal-title":"Circulation"},{"key":"CR131","first-page":"948","volume":"65","author":"B Steiner","year":"1991","unstructured":"Steiner B, Hadvary P, Roux S, Weller T. Selective inhibitors of platelet GPIIb\/IIIa (abstr). Thromb Haemost 1991;65:948.","journal-title":"Thromb Haemost"},{"key":"CR132","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/0002-8703(88)90796-X","volume":"115","author":"M Chiariello","year":"1988","unstructured":"Chiariello M, Golino P, Cappelli-Bagazzi M, et al. Reduction in infarct size by the prostacyclin analogue iloprost (ZK 36374) after experimental coronary artery occlusion reperfusion. Am Heart J 1988;115:499?504.","journal-title":"Am Heart J"},{"key":"CR133","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/0022-2828(88)90590-1","volume":"20","author":"R Ferrari","year":"1988","unstructured":"Ferrari R, Cargnoni A, Ceconi C, et al. Protective effect of a prostacyclin mimetic on the ischaemic reperfused rabbit myocardium. J Mol Cell Cardiol 1988;20:1095?1106.","journal-title":"J Mol Cell Cardiol"},{"key":"CR134","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/0735-1097(89)90458-0","volume":"14","author":"EJ Topol","year":"1989","unstructured":"Topol EJ, Ellis SG, Califf RM, et al. Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. J Am Coll Cardiol 1989;14:877?884.","journal-title":"J Am Coll Cardiol"},{"key":"CR135","first-page":"783","volume":"65","author":"W Witt","year":"1991","unstructured":"Witt W, Loge O, M\ufffdller B, et al. Combinations of aspirin and oral PGI2-mimetic cicaprost show synergistic antithrombotic efficacy and reduced gastrointestinal bleeding (abstr). Thromb Haemost 1991;65:783.","journal-title":"Thromb Haemost"},{"key":"CR136","first-page":"1283","volume":"65","author":"PFJ Verhallen","year":"1991","unstructured":"Verhallen PFJ, Kahleyss T, Witt W, Thierach KH. Synergistic inhibition of platelet activation by the prostacyclin-analogue cicaprost and aspirin. Implications for multiple mechanisms for downregulation of the cAMP pathway (abstr). Thromb Haemost 1991;65:1283.","journal-title":"Thromb Haemost"},{"issue":"Suppl III","key":"CR137","first-page":"52","volume":"82","author":"S Saitho","year":"1991","unstructured":"Saitho S, Saitho T, Asakura T, et al. New antiplatelet agent, beraprost (PGI2 analogue) prevents reocclusion in myocardial infarction model (abstr). Circulation 1991;82 (Suppl III):52.","journal-title":"Circulation"},{"issue":"Suppl III","key":"CR138","first-page":"537","volume":"82","author":"FW B\ufffdr","year":"1990","unstructured":"B\ufffdr FW, Meyer J, Uebis R, et al. Does taprostene influence patency and reocclusion in myocardial infarction treated with the thrombolytic agent saruplase (abstr)? Circulation 1990;82 (Suppl III):537.","journal-title":"Circulation"},{"key":"CR139","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1055\/s-0038-1648154","volume":"65","author":"N Suzuki","year":"1991","unstructured":"Suzuki N, Kitazato K, Takamatsu J, Saito H. Antithrombotic and anticoagulant activity of depolymerized fragment of the glycosaminoglycan extracted from Stichopus Jaganicus Selenka. Thromb Haemost 1991;65:369?373.","journal-title":"Thromb Haemost"},{"key":"CR140","first-page":"351","volume-title":"The pharmacology and toxicology of proteins","author":"SC Emerick","year":"1987","unstructured":"Emerick SC, Murayama H, Yan SB, et al. Preclinical pharmacology of activated protein C. In: Hollenberg JC, Winkenhale J, eds. The pharmacology and toxicology of proteins. New York: Alan R. Liss, 1987:351?367."},{"key":"CR141","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood.V73.3.639.639","volume":"73","author":"A Gruber","year":"1989","unstructured":"Gruber A, Griffin JH, Harker LA, Hanson R. Inhibition of platelet dependent thrombus formation by human activated protein C in a primate model. Blood 1989;73:639?642.","journal-title":"Blood"},{"key":"CR142","first-page":"1189","volume":"5","author":"BW Grinnell","year":"1987","unstructured":"Grinnell BW, Berg DT, Walls J, Yan SB. Trans-activated expression of fully gamma-carboxylated recombinant human protein C, an antithrombotic factor. Bio\/Technology 1987;5:1189?1192.","journal-title":"Bio\/Technology"},{"key":"CR143","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1161\/01.CIR.82.2.578","volume":"82","author":"A Gruber","year":"1990","unstructured":"Gruber A, Hanson SR, Kelly AB, et al. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation 1990;82: 578?585.","journal-title":"Circulation"},{"key":"CR144","doi-asserted-by":"crossref","first-page":"16694","DOI":"10.1016\/S0021-9258(19)84761-0","volume":"264","author":"C Dunwiddie","year":"1989","unstructured":"Dunwiddie C, Thornberry NA, Bull HJG, et al. Antistasin, a leech-derived inhibitor of factor Xa. J Biol Chem 1989; 264:16694?16699.","journal-title":"J Biol Chem"},{"key":"CR145","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1126\/science.2333510","volume":"248","author":"L Waxman","year":"1990","unstructured":"Waxman L, Smith DE, Acuri KE, Vlassuk GP. Tick anticoagulant peptide in a novel inhibitor of blood coagulation factor Xa. Science 1990;248:593?596.","journal-title":"Science"},{"issue":"Suppl III","key":"CR146","first-page":"660","volume":"82","author":"LW Schaffer","year":"1990","unstructured":"Schaffer LW, Davidson JT, Vlasuk G, Siegl PKS. Antithrombotic effect of the factor Xa inhibitor tick anticoagulant peptide (TAP) in a baboon model of acute arterial thrombosis (abstr). Circulation 1990;82 (Suppl III):660.","journal-title":"Circulation"},{"issue":"Suppl III","key":"CR147","first-page":"603","volume":"82","author":"G Vlassuk","year":"1990","unstructured":"Vlassuk G, Sitko G, Shebuski R. Specific factor Xa inhibition enhances thrombolytic reperfusion and prevents acute reocclusion in the canine copper coil model of arterial thrombosis (abstr). Circulation 1990;82: (Suppl III):603.","journal-title":"Circulation"},{"key":"CR148","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/1053-0770(91)90099-F","volume":"5","author":"RA Johns","year":"1991","unstructured":"Johns RA. Endothelium-derived relaxing factor: Basic review and clinical implications. J Cardiothorac Vasc Anesth 1991;5:69?79.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"CR149","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00019501-199105000-00002","volume":"2","author":"V Schini","year":"1991","unstructured":"Schini V. Nitric oxide and vascular reactivity. Cor Artery Dis 1991;2:293?299.","journal-title":"Cor Artery Dis"},{"issue":"Suppl A","key":"CR150","first-page":"5","volume":"12","author":"EE \ufffdngg\ufffdrd","year":"1991","unstructured":"\ufffdngg\ufffdrd EE. Endogenous nitrates-Implications for treatment and prevention. Eur Heart J 1991;12 (Suppl A):5?8.","journal-title":"Eur Heart J"},{"key":"CR151","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/327524a0","volume":"327","author":"RM Palmer","year":"1987","unstructured":"Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium derived relaxing factor. Nature 1987;327:524?526.","journal-title":"Nature"},{"key":"CR152","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/0140-6736(90)90462-E","volume":"335","author":"R Korbut","year":"1990","unstructured":"Korbut R, Lidbury PS, Vane JR. Prolongation of fibrinolytic activity of tissue plasminogen activator by nitrovasodilators. Lancet 1990;335:669.","journal-title":"Lancet"},{"issue":"Suppl III","key":"CR153","first-page":"301","volume":"82","author":"H Darius","year":"1990","unstructured":"Darius H, Grodzinska L, Hafner G. No-releasing molsidomine increases fibrinolytic activity in man (abstr). Circulation 1990;82 (Suppl III):301.","journal-title":"Circulation"},{"key":"CR154","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/0140-6736(91)90202-Z","volume":"337","author":"N Sharpe","year":"1991","unstructured":"Sharpe N, Smith H, Murphy J, et al. Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting enzyme inhibitors. Lancet 1991;337:872?876.","journal-title":"Lancet"},{"key":"CR155","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0735-1097(91)91427-G","volume":"17","author":"A Pipilis","year":"1991","unstructured":"Pipilis A, Flather M, Collins R, et al. ISIS-4 pilot study: Serial hemodynamic changes with oral captopril and oral isosorbide mononitrate in a randomized double-blind trial in myocardial infarction (abstr). J Am Coll Cardiol 1991;17:115.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl II","key":"CR156","first-page":"II112","volume":"80","author":"EG Nabel","year":"1989","unstructured":"Nabel EG, Topol EJ, Galeana A, et al. A randomized, double-blind, placebo controlled, pilot trial of combined early intravenous captopril and tPA therapy in acute myocardial cardial infarction (abstr). Circulation 1989;80 (Suppl II):II112.","journal-title":"Circulation"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00054557.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00054557\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00054557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T05:09:25Z","timestamp":1624856965000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00054557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,4]]},"references-count":156,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1992,4]]}},"alternative-id":["BF00054557"],"URL":"https:\/\/doi.org\/10.1007\/bf00054557","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,4]]}}}